• InMed’s all-stock merger with privately held Mentari Therapeutics was amended to clarify deal sequencing, exchange-ratio effects from pre-closing financing, and intended tax treatment.
• A registration statement on Form S-4 was filed, including a preliminary proxy statement/prospectus and management information circular for the transaction.
• The companies continue to target closing in Q4 2026, subject to shareholder and stockholder votes and other customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-077127), on July 10, 2026, and is solely responsible for the information contained therein.